Printer Friendly

Ark Therapeutics, PsiOxus strike manufacturing deal.

M2 PHARMA-September 12, 2011-Ark Therapeutics, PsiOxus strike manufacturing deal(C)2011 M2 COMMUNICATIONS

12 September 2011 - UK-based Ark Therapeutics Group plc (LON:AKT) said on Monday it had sealed a manufacturing partnership deal with PsiOxus Therapeutics Ltd.

Under the agreement, Ark will provide full manufacturing and related services to support the development of PsiOxus' ColoAd1 programme for the treatment of colorectal cancer.

Ark will work with PsiOxus in providing oncolytic adenoviral material for IV administration in toxicological and Phase I/II trials, utilising Ark's suspension based single use system (ATOSUS).

Besides providing manufacturing capabilities, PsiOxus will benefit from Ark's experience in the regulatory CMC aspects of developing a gene-based medicine, said Martyn Williams, Ark's CEO.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 12, 2011
Words:126
Previous Article:Janssen Biotech receives FDA Complete Response letter for SIMPONI sBLA.
Next Article:Nektar presents promising Phase II results for NKTR-102 in metastatic breast cancer.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters